CSI Market
Sign In | Register

Apellis Pharmaceuticals Inc (APLS) Annual Cash Flow Statement

Annual · GAAP · USD millions
Access APLS quarterly Cash Flow →
The cash flow figures below highlight longer-term patterns in how Apellis Pharmaceuticals Inc manages cash inflows and outflows over time.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Annual Report, GAAP in USD millions
ITEM 		(Dec 31 2025)
12 Months 		(Dec 31 2024) (Dec 31 2023) (Dec 31 2022) (Dec 31 2021)
Operating Activities
Income22.39
Depreciation & amortization1.56
Amortization of Other Assets0.00
Increase (Decrease) in Deferred Revenue0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Increase (Decrease) in Inventories-15.27
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets, Total0.00
Share-based Compensation104.00
Income (Loss) from Equity Method Investments0.00
Gains (Losses) on Extinguishment of Debt0.00
Derivative Gain Loss On Derivative Net-
Amortization Of Discounts For Promissory Note-
Amortization Of Term Loan Facility Discounts-
Amortization Of Discounts For Convertible Notes Net Of Financing Costs-
Loss On Conversion Of Debt-
Amortization Of Discounts For Convertible Notes-
Loss On Extinguishment Of Development Liability-
Issuance Costs For Credit Facility Incurred But Not Yet Paid-
Amortization Of Discounts For Credit Facility And Convertible Notes2.50
Accretion Of Discount To Development Liability-
Increase Decrease In Right Of Use Assets And Lease Liabilities-0.03
Income taxes0.00
Losses/ -gains on Investments net0.00
Increase (Decrease) in Accounts Receivable-101.28
Increase (Decrease) in Accounts Payable18.22
Increase (Decrease) in Accrued Liabilities25.39
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets-8.09
Other Working Capital-4.06
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities0.00
Discontinued operations0.00
Net Cash flow from Operating Activities45.33
Investing Activities
Capital Expenditures-0.31
Sale of Capital Items0.00
Proceeds from Maturities, Prepayments and Calls of Available-for-sale Securities0.00
Payments to Acquire Available-for-sale Securities, Debt0.00
Real Estate Investments0.00
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-0.31
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock8.90
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net-412.62
Proceeds From Issuance Of Promissory Notes Payable To Affiliate Of Stockholder-
Proceeds From Stock Options And Warrants Exercised-
Proceeds From Development Derivative Liability-
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents412.61
Proceeds From Payments For Development Derivative Liability-
Payments For Capped Call Transactions And Associated Costs-
Proceeds From Issuance Of Convertible Notes Net Of Issuance Costs-
Proceeds From Issuance Of Common Stock And Pre Funded Warrant Offering Net Of Issuance Costs-
Payments For Development Liability-
Repayment Of Development Liability-
Proceeds From Settlement Of Capped Call-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities8.88
Effect of exchange rate on cash flow1.25
Discontinued operations0.00
Free Cash Flow45.01
Total Cash Flow55.15
4 historic quarters locked

Sign in to unlock the full Apellis Pharmaceuticals Inc cash flow history.

Sign In Create Free Account

About Apellis Pharmaceuticals Inc Annual Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-K filings and normalized by CSIMarket.

Source & verification

  • Form: 10-K (Period: 20251231)
  • Filed with the SEC: February 24, 2026
  • Source: apls-20251231.htm

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001193125-26-065179

Figures are derived from filed reports and may be restated. Historical data is subject to revision.

Untitled Document